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K-ras Oncogene Codon 12 Point Mutations in
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Onfelt,3 Sophie Foss ,2 Anne-Lise B0rresen, and
Kirsti Husgafvel-Pursiainen1
A significant association between N-ras oncogene activating point mutations and testicular cancer has
recentlybeen reported. We have studied DNA samples fromthe blood andfresh tumortissues of17 Norwegian
testicularcancerpatients (Useminomas/6nonseminomas).Pointmutations in K-ras-2andN-ras exons 1 and2
were studied by denaturing gradient gel electrophoresis (DGGE) and by oligonucleotide hybridization. No
N-ras mutations were detected in these tumorsamples, buttwo K-ras-2 exon 1 mutationswere found in twoof
theseminomatumors(stage I andII tumors)usingtheDGGEtechnique.Themutationswereconfirmedbydot
blottingandoligonucleotide hybridization andidentifiedasaG->TandaG-Apointmutation inK-ras-2codon
12, leadingto avaline and aserine substitution, respectively. All the white blood cell DNAswere negative.As a
positive control forDGGE screening, we ran two plasmid constructs carrying human N-ras exon 2 sequences
with mutations. To studythe role ofras gene activation in testicularcancer, alargertumorsample population
will be investigated.
Introduction
Testicular cancer is one of the most frequent cancers
among young men. A higher risk oftesticular cancer has
been associated with certain subpopulations, e.g., men of
highersocioeconomic statusand someoccupational groups
such as paper and printing workers, professionals, and
administrators (1). Other anatomic, genetic, and environ-
mental risk factors also exist.
The most common activated oncogenes in human can-
cers are ras oncogenes (2). This oncogene family contains
three closely related cellular genes: K-ras-2, H-ras-1, and
N-ras (3). The ras genes are almost exclusively activated
by single base-pair substitutions (4), most frequently in
codons12,13, or61. Differentmembers ofthe ras oncogene
family are activated in various types of cancer (2,5). In
testicular cancer, N-ras point mutations have frequently
been detected incodons12and61(6,7). However, Mulderet
al. (6) also reported K-ras-2 codon 12base substitutions in
a few ofthe cases.
We studied K-ras-2 and N-ras mutations in samples from
17 Norwegian testicular cancerpatients by denaturing gra-
dient gel electrophoresis (DGGE) and by dot blotting and
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oligonucleotide hybridization (8,9). The combination of
these techniques has turned out to be suitable for rapidly
screening for mutations in ras oncogenes (10). DGGE is
based on the ability ofDNAto melt in different sequence-
dependent domains. Theoretically, one base pair substitu-
tion in a lower melting domain is enough to change the
melting behavior ofa DNA sequence (11-13).
Materials and Methods
DNA samples from the peripheral blood and fresh
tumor tissue of 17 Norwegian testicular cancer patients
were studied. The patients were 22-53 years old at the
timeofdiagnosis, andtheyareasubgroupofcasesalready
described by Lothe et al. (14). According to a light micro-
scopic diagnosis, 11 ofthe patients had a unilateral semi-
noma and 6 had a unilateral nonseminoma.
K-ras-2 and N-ras exons 1 and 2 were amplified sepa-
rately by the polymerase chain reaction (PCR) using
AmpliTaq-DNApolymerase (Cetus). In each ofthe PCRs,
one oftheprimershad aGC-richoligonucleotide sequence
of40basepairs(aGC-clamp),whichwasintroduced atone
end of the amplified sequences (15,16). Sequences for the
primers are given elsewhere (Ridanpaiii and Husgafvel-
Pursiainen, submitted.). The length ofthe PCR products
varied between 150 and 175base-pairs.
Aliquots ofthePCRproductswereanalyzedindenatur-
ing gradient gel electrophoresis (DGGE). Perpendicular
and parallel gels were run using 7.5% polyacrylamide gels
containing a linear gradient of chemical denaturants. InRIDANPAA ETAL.
the perpendicular gels, the gradientwas 0-50% andin the
parallel gels itwas 25-40% (100% denaturant = 7 M urea
and40%formamide).Allgelswererun at60°C in abath of
Tris-acetate-EDTA (TAE) buffer at pH 8.0. The gels were
stained with ethidium bromide in distilled water before
photographing under UV light.
Twoplasmidscarryingasinglebase-pairsubstitutionin
humanN-ras codon61(CAA->AAAandCAA-*CAC)were
constructed (16). After in vitro amplification, the N-ras
mutant sequences were run in DGGE as a control for the
separation of the mutant bands from the wild-type ones.
Specimens from the same PCR products were dotblotted
on nylon membranes (Hybond) with a set of positive
control DNAs for activating point mutations in K-ras-2
and N-ras in codons 12,13, and 61 (Clonetech Laborato-
ries). 32P-end-labeled oligonucleotide probing, hybridiza-
tion, and washing procedures were done according to the
manufacturer's recommendation. Autoradiography films
(Amersham) were exposed at -70°C using intensifying
screens.
Results
Among11 seminomas, thereweretwo cases (stage I and
II) thatwere observed to carry a K-ras-2 exon 1 mutation
by DGGE. A clear separation between the homoduplex
wild-type band and the mutant homoduplex bands were
obtained. By oligonucleotide hybridization, these two
mutations were identified to be a G->T transversion
(glycine to valine substitution) and a G->A transition
(serine substituted forglycine)inK-ras-2codon12 (Fig.1).
The rest of the seminoma samples and all of the non-
seminoma samples showed neither N-ras nor other
K-ras-2 mutations (Table 1).
Thetwoinvitroamplified N-rassequenceseachcarrying
a single base-pair substitution in codon 61 (CAA->AAA,
CAA-4CAC) gave a good separation in the denaturing
gradientgels (Fig. 2). In tumor samples, in addition to the
well-separated homoduplex bands, heteroduplexes were
seen on the denaturing gradient gels. The heteroduplex
1 2 3 1 2 3
A ~~~~B
FIGURE 1. Detection ofpoint mutations in K-ras-2 exon 1 by denaturing
gradient gel electrophoresis. Testicular tumor sampleson a parallel gel
(denaturing concentration 25-40%). (A) Lane 1 shows a mutation (codon
12 valine, GGT---GTT). (B) Lane 2 shows a mutation (codon 12 serine,
GGT->AGT). In both figures the other lanes represent wild-type.
Table 1. The set oftesticular tumor samples studies.a
Mutations in
K-ras-2 exon 1 Amino acid
Histological diagnosis No. oftumors (codon 12) substitution
Seminoma 11 2 Serine-12
Valine-12
Nonseminoma
Embryonal carcinoma 3 None
Endodermal sinus tumor 2 None
Mature teratoma 1 None
aNo K-ras-2 exon 2 (condon 61) or N-ras mutations were detected.
1 2 3
FIGURE 2. Detection ofpoint mutations in N-ras exon 2 in a parallel
gel electrophoresis (denaturing gradient 25-40%). (Lane 1) Positive
control sequence carrying codon 61 lysine (AAA); (Lane 2) positive
control sequence carrying codon 61 histidine-2 (CAC); (Lane 3) N-ras
exon 2 codon 61 wild-type (CAA).
bands ofthe valine mutant displayed greater separation
than the heteroduplex bands ofthe serine mutant, thus
facilitating the identification ofthe mutants.
Discussion
N-ras point mutations in codons 12 and 61 have been
detected in 4/14 (6) and 20/31 (7) tumors of testicular
cancer. In addition, Mulder et al. (6) reported two K-ras-2
codon 12 mutations in a group of14 testicular cancers. In
thepresentstudy,theonlyrasgenemutationsfoundinthe
freshtesticulartumorsamplesfrom17patientswerethose
in K-ras-2 codon 12. Both of the K-ras-2 mutations were
detected in seminoma tumors, one being a stage I and the
other a stage II tumor. This is in accordance with the
reported higher incidence of ras gene mutations in semi-
noma as compared to nonseminoma tumors (7).
Comparedto ourfindingsinlungcancer,usingasimilar
approach (10), theobserved K-ras-2mutationfrequencyin
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testicular cancer seems to be much lower. In lung ade-
nocarcinoma, ras gene activation seems to occur in early
stages oftumordevelopment and hasbeen associated with
poor prognosis (17). Most of the mutations found in lung
adenocarcinomas arereported tobe G-Ttransversions in
K-ras-2 (10,15) andthemutation type appearstobeassoci-
ated with smoking (18). In the literature, however, no such
qualitative predominance in the types of base-pair sub-
stitutions in K-ras-2 or N-ras genes has been found in
testicular cancer (6,7). The amount of cancer, however, is
too small to draw any firm conclusions about the nature
and the frequency ofthe ras oncogene mutations in testi-
cular cancer. To further elucidate the role and type ofras
gene mutations in testicular cancer, we are now in the
process of cases investigating a larger set oftumor sam-
ples.
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